The antitumor effects of selenium compound Na5SeV5O18·3H2O in K562 cell

Vanadium Compounds as Enzyme Inhibitors with a Focus on Anticancer Effects

Vanadium salts and coordination compounds have desirable cellular anticancer effects, and although they have been investigated in detail as a potential treatment for diabetes, less attention has been given to the anticancer effects. The inhibition of some signal transduction enzymes is known, and studies of the metabolism and activation pathways both in vitro and in vivo are important for future investigations and development of vanadium's role as a new potential drug. In addition, a new approach has demonstrated that the enhancement of oncolytic viruses using vanadium salts and coordination complexes for immunotherapy is very promising. Some differences exist between this approach and current antidiabetic and anticancer studies because vanadium(iv) complexes have been found to be most potent in the latter approach, but the few compounds investigated with oncolytic viruses show that vanadium(v) systems are more effective. We conclude that recent studies demonstrate effects on signal transduction enzymes and anticancer pathways, thus suggesting potential applications of vanadium as anticancer agents in the future both as standalone treatments as well as combination therapies.

Se2Mo10V3, a heteropoly compound containing selenium, inhibits tumor growth

Selenium compounds have strong anti-tumor effects and are well-tolerated. We examined the anti-tumor effects of (NH₄)₂H₁₅Se₂^VIMo₁₀V₃O₅₂·2H₂O (Se₂Mo₁₀V₃₎, a heteropoly compound containing selenium. Se₂Mo₁₀V₃ inhibited proliferation in K562 cells with a half-maximal inhibitory concentration of 78.72±2.82 mg/L after 48 h and 24.94±0.88 mg/L after 72 h. Typical apoptotic morphologies were also observed in K562 cells treated with Se₂Mo₁₀V₃, as were increased intracellular levels of Ca²⁺, Mg²⁺, H⁺, and reactive oxygen species, and decreased mitochondrial membrane potential. In addition, Se₂Mo₁₀V₃ treatment triggered cytochrome C release and inhibited IκBα degradation and NF-κB translocation. In vivo experiments revealed that 5 or 10 mg/kg Se₂Mo₁₀V₃ inhibited the growth of sarcoma 180 and hepatoma 22 xenograft tumors. These results indicate that Se₂Mo₁₀V₃ inhibits tumor growth both in vitro and in vivo and induces apoptosis in K562 cells, possibly by inhibiting the NF-κB/IκBα pathway.

Localized drug delivery of selenium (Se) using nanoporous anodic aluminium oxide for bone implants

Release behavior and cancer toxicity of different forms of Se loaded into nanoporous AAO were studied.